Baylis Medical Company, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Baylis Medical Company, Inc
AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.
GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.
Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.
Going Early For Maximum Long Term Value From Medtech Deals
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
- Medical Devices
- Diagnostic Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Implantable Devices
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- CNP Therapeutics
- Fralex Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.